ClinicalTrials.gg
CompletedNCT02319031Updated Jan 27, 2017Results posted

Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

A Phase 3 interventional study of Daclatasvir and Sofosbuvir in Hepatitis C, sponsored by Bristol-Myers Squibb. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
53
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing daclatasvir in Hepatitis C — 1 open to participants now, 2 under way, 1 of them phase 3. daclatasvir · Hepatitis C.

Enrollment
39th of 59
53 · median 100
Started
2015
with 8 others
Phase 3
24 of 59
none open now
Registered
42nd of 59
by date
Lead sponsor
42 of 59
Bristol-Myers Squibb

Among the 59 studies testing daclatasvir in Hepatitis C, this one is the 39th largest by enrollment, is one of 9 that started in 2015, is one of 24 in phase 3, and was the 42nd registered.

Hepatitis C

1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.

Browse Hepatitis C studies →

Open to participants now

1 of the 59 studies testing daclatasvir in Hepatitis C is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About daclatasvir

daclatasvir: first FDA approval 2015 (DAKLINZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing daclatasvir in Hepatitis C, or all of them as a file.
02

Study summary

The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced fibrosis or compensated cirrhosis. Patients in this study may have already been treated prior for HCV or may have never received treatment for their HCV.

03

Conditions studied

  • Hepatitis C

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Must have Genotype 3 Chronic
  • Must have advanced fibrosis (F3) or compensated cirrhosis (F4)
  • HCV RNA Viral load ≥ 10,000 IU/mL
  • HCV Treatment naive or treatment-experienced

Exclusion criteria

Exclusion Criteria:

  • Non Genotype 3 or mixed genotypes
  • Non advanced fibrosis or compensated cirrhosis
  • Any prior treatment with NS5A inhibitors
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Active comparator
    Arm1: Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)

    Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing

    Drug: Daclatasvir · Drug: Sofosbuvir · Drug: Ribavirin

  • Active comparator
    Arm2 : Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)

    Oral dosing Daclatasvir 60mg once daily, Sofosbuvir 400mg once daily, and Ribavirin 1000-1200mg (weight based dosing) split into am and pm dosing

    Drug: Daclatasvir · Drug: Sofosbuvir · Drug: Ribavirin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)

    SVR12, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 12. SVR12 imputation was based on Next Value Carried Backwards (NVCB) approach. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.

    Time frame: Follow-up Week 12

Secondary outcomes

  1. Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 4 (SVR4) and Follow-up Week 24 (SVR24)

    SVR4, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 4. SVR24, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 24. SVR4 imputation was based on Next Value Carried Backwards (NVCB) approach. SVR24 imputation was based on missing being treated as non-responder. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.

    Time frame: Follow-up Weeks 4 and 24

  2. Number of Participants With Death, Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), Grade 3 or Grade 4 (Grade 3/4) AEs, and Grade 3/4 Laboratory Abnormalities

    Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. The degree of the adverse event or laboratory abnormality are evaluated by grades: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Grading as per using National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0 criteria.

    Time frame: Date of First Dose of Study Drug to 7 Days post last dose of study drug (up to 13 weeks or 17 weeks depending on the randomized treatment group)

07

Results

Posted Jan 27, 2017

Participant flow

53 participants were enrolled. 50 participants were randomized and treated (24 to 12 week arm, 26 to 16 week arm). Reason for non-randomization was 3 no longer met study criteria.

Treatment Period
Participant flow — Treatment Period
MilestoneDaclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)
Started2426
Completed2326
Not completed10
Withdrew: Death10
Follow-Up Period
Participant flow — Follow-Up Period
MilestoneDaclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)
Started2326
Completed2326
Not completed00

Outcome measures

PrimaryPercent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)

SVR12, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 12. SVR12 imputation was based on Next Value Carried Backwards (NVCB) approach. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.

Time frame:
Follow-up Week 12
Reported as:
Number · percentage of participants
Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)
percentage of participantsDaclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)
Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)87.5 (67.6 to 97.3)92.3 (74.9 to 99.1)
SecondaryPercent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 4 (SVR4) and Follow-up Week 24 (SVR24)

SVR4, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 4. SVR24, defined as percentage of participants with hepatitis C virus (HCV) ribonucleic acid (RNA) \< lower limit of quantitation (LLOQ), target detected (TD) or target not detected (TND) at follow-up Week 24. SVR4 imputation was based on Next Value Carried Backwards (NVCB) approach. SVR24 imputation was based on missing being treated as non-responder. HCV RNA measurements were excluded after the start of non-study anti-HCV medication on treatment or during follow-up.

Time frame:
Follow-up Weeks 4 and 24
Reported as:
Number · percentage of participants
Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 4 (SVR4) and Follow-up Week 24 (SVR24)
percentage of participantsDaclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)
Follow-up Week 4 (SVR4)87.5 (67.6 to 97.3)96.2 (80.4 to 99.9)
Follow-up Week 24 (SVR24)87.5 (67.6 to 97.3)92.3 (74.9 to 99.1)
SecondaryNumber of Participants With Death, Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), Grade 3 or Grade 4 (Grade 3/4) AEs, and Grade 3/4 Laboratory Abnormalities

Serious adverse event (SAE) defined: a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Adverse event (AE) defined: any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. The degree of the adverse event or laboratory abnormality are evaluated by grades: Grade (Gr) 1=Mild, Gr 2=Moderate, Gr 3=Severe, Gr 4=Life-threatening or disabling, Gr 5=Death. Grading as per using National Cancer Institute Common Terminology Criteria (NCI CTC) Version 3.0 criteria.

Time frame:
Date of First Dose of Study Drug to 7 Days post last dose of study drug (up to 13 weeks or 17 weeks depending on the randomized treatment group)
Reported as:
Number · participants
Number of Participants With Death, Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), Grade 3 or Grade 4 (Grade 3/4) AEs, and Grade 3/4 Laboratory Abnormalities
participantsDaclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)
Death10
SAEs23
Discontinuation due to AEs00
Grade 3/4 AEs22
Grade 3/4 Laboratory Abnormalities12

Adverse events

Collected over SAEs were reported from date of first dose of study drug to 30 days post discontinuation of the last dose which was up to 16 weeks or 20 weeks depending on the randomized treatment group. Non-serious AEs were reported from date of first dose of study drug to 7 days post discontinuation of the last dose which was up to 13 weeks or 17 weeks depending on the randomized treatment group.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)—2/24 (8.3%)21/24 (87.5%)
Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)—3/26 (11.5%)22/26 (84.6%)
Most frequent serious events
Most frequent serious events
EventDaclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)
SomnolenceNervous system disorders1/240/26
Congestive cardiomyopathyCardiac disorders1/240/26
ArteriosclerosisVascular disorders0/241/26
PneumoniaInfections and infestations0/241/26
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/241/26
Most frequent other events
Showing 10 of 23
Most frequent other events
EventDaclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)
InsomniaPsychiatric disorders8/247/26
HeadacheNervous system disorders7/245/26
FatigueGeneral disorders6/247/26
IrritabilityPsychiatric disorders5/242/26
AstheniaGeneral disorders1/245/26
DiarrhoeaGastrointestinal disorders1/244/26
NauseaGastrointestinal disorders3/241/26
DyspnoeaRespiratory, thoracic and mediastinal disorders2/243/26
Back painMusculoskeletal and connective tissue disorders0/243/26
HypertensionVascular disorders0/243/26

Baseline characteristics

Treated Population: All enrolled participants who received at least 1 dose of study drug

Age, Continuous
Age, Continuous(years)Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)Total
Mean53.0 ± 7.7755.0 ± 5.7554.1 ± 6.80
Age, Customized
Age, Customized(participants)Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)Total
<65232649
>=65101
Gender
Gender(Participants)Daclatasvir + Sofosbuvir + Ribavirin (12 Weeks)Daclatasvir + Sofosbuvir + Ribavirin (16 Weeks)Total
Female6410
Male182240
08

Study locations

10 sites
  • Local Institution
    Darlinghurst, New South Wales 2010, Australia
  • Local Institution
    Greenslopes, Queensland 4120, Australia
  • Local Institution
    Adelaide, South Australia 5000, Australia
  • Local Institution
    Clayton, Victoria 3168, Australia
  • Local Institution
    Fitzroy, Victoria 3065, Australia
  • Local Institution
    Heidelberg, Victoria 3084, Australia
  • Local Institution
    Creteil Cedex, 94010, France
  • Local Institution
    Grenoble Cedex 09, 38043, France
  • Local Institution
    Paris Cedex 14, 75679, France
  • Local Institution
    Vandoeuvre Les Nancy, 54511, France
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Oct 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2017, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2014
First posted
Dec 18, 2014
Start
Feb 2015
Primary completionActual
Oct 2015
CompletionActual
Dec 2015
Results first posted
Jan 27, 2017
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02319031
Responsible party
Sponsor
First posted
Dec 18, 2014
Start date
Feb 2015
Primary completion
Oct 2015
Completion
Dec 2015
Results posted
Jan 27, 2017
Last update
Jan 27, 2017

Study contacts

Bristol - Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Daclatasvir · Sofosbuvir · Ribavirin

Start the discussion